What’s New in CLL?
- ASH 2020: Dr. Arnon Nagler on Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation After Targeted Therapy for CLL
- Dr. Rick Furman Discusses COVID-19 and the Vaccines in CLL Patients, Live at the New York City CLL Society Support Group Meeting
- Explaining to Family and Friends Why the CDC Guidelines for Those Vaccinated Against COVID-19 Do Not Apply to CLL Patients
- ASH 2020: Dr. Tanya Siddiqi Provides an Update on the TRANSCEND CLL 004 Trial: Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) CLL/SLL
Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support and research. Dedicated to addressing the unmet needs of the (CLL) chronic lymphocytic leukemia and
related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials,
support and build patient networks, engage in research and educate providers and patients.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. In partnership with Verastem Oncology (Expert Access Founding Supporter), Genentech, and InfiniteMD, the CLL Society is proud to offer this free second opinion program for CLL patients.
We Are in this Together
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL